Screener
Xeris Biopharma Holdings, Inc. XERS Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $92.1M+28.7% | $83.13M+38.3% | $85.81M+42.8% | $74.38M+37.1% | $71.54M+48.8% | ||
| $12.51M+5.2% | $10.57M+21.2% | $10.95M+15.5% | $11M-19.1% | $11.9M+52.7% | ||
| $10.67M+32.5% | $8.78M+13.3% | $7.87M+29.3% | $7.48M+27.1% | $8.06M+39.9% | ||
| $61.04M+37.5% | $53.14M+20.7% | $47.5M+18.3% | $46.46M+3.3% | $44.39M+11.0% | ||
| $86.93M+29.6% | $75.21M+19.0% | $69.03M+18.2% | $67.65M+0.7% | $67.06M+19.2% | ||
| $5.17M+15.4% | $7.92M+356% | $16.77M— | $6.73M+152% | $4.48M+155% | ||
| 5.6%-0.6pp | 9.5%+14.7pp | 19.5%+19.5pp | 9%+32.8pp | 6.3%+23.3pp | ||
| $6.95M-5.6% | $6.88M-5.8% | $7.15M-7.1% | $7.27M-6.7% | $7.36M-7.6% | ||
| -$36.27M-466% | -$5.68M+7.3% | -$5.69M+16.2% | -$6.11M+1.0% | -$6.41M-5.6% | ||
| $0— | $0— | $0— | $0+100% | $0-100% | ||
| -$31.1M-1,513% | $2.23M+124% | $11.08M+317% | $621K+104% | -$1.93M+87.2% | ||
| -33.8%-31.1pp | 2.7%+18.0pp | 12.9%+21.4pp | 0.8%+29.8pp | -2.7%+28.5pp | ||
| -$0.18-1,700% | $0.01+117% | $0.07+333% | $0.00+100% | -$0.01+90.0% | ||
| $5.5M+14.3% | $8.25M+397% | $17.11M+5,366% | $7.07M+156% | $4.81M+161% | ||
| 6%-0.8pp | 9.9%+14.5pp | 19.9%+19.4pp | 9.5%+32.7pp | 6.7%+23.2pp | ||
| $5.17M+15.4% | $7.92M+356% | $16.77M— | $6.73M+152% | $4.48M+155% |
FAQ
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $335.4M in revenue over the trailing twelve months, up 36.3% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. is not currently profitable: it reported a net loss of $17.2M over the trailing twelve months, a -5.1% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 86.6% and operating margin is 10.9%, with a -5.1% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $-0.10.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
